| Literature DB >> 35839780 |
Stuti Mehta1, Altantsetseg Buyanbat1, Yan Kai1, Ozge Karayel2, Seth Raphael Goldman3, Davide Seruggia4, Kevin Zhang1, Yuko Fujiwara1, Katherine A Donovan5, Qian Zhu1, Huan Yang1, Behnam Nabet6, Nathanael S Gray7, Matthias Mann2, Eric S Fischer5, Karen Adelman3, Stuart H Orkin8.
Abstract
Reactivation of fetal hemoglobin expression by the downregulation of BCL11A is a promising treatment for β-hemoglobinopathies. A detailed understanding of BCL11A-mediated repression of γ-globin gene (HBG1/2) transcription is lacking, as studies to date used perturbations by shRNA or CRISPR-Cas9 gene editing. We leveraged the dTAG PROTAC degradation platform to acutely deplete BCL11A protein in erythroid cells and examined consequences by nascent transcriptomics, proteomics, chromatin accessibility, and histone profiling. Among 31 genes repressed by BCL11A, HBG1/2 and HBZ show the most abundant and progressive changes in transcription and chromatin accessibility upon BCL11A loss. Transcriptional changes at HBG1/2 were detected in <2 h. Robust HBG1/2 reactivation upon acute BCL11A depletion occurred without the loss of promoter 5-methylcytosine (5mC). Using targeted protein degradation, we establish a hierarchy of gene reactivation at BCL11A targets, in which nascent transcription is followed by increased chromatin accessibility, and both are uncoupled from promoter DNA methylation at the HBG1/2 loci.Entities:
Keywords: BCL11A; DNA methylation; PROTAC; chromatin accessibility; dTAG; erythropoiesis; globin regulation; nascent transcription; proteomics; sickle-cell disease, SCD; β-thalassemia
Mesh:
Substances:
Year: 2022 PMID: 35839780 PMCID: PMC9391307 DOI: 10.1016/j.chembiol.2022.06.007
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 9.039